For the year ending 2025-12-31.
| Income Statement | 2025-12-31 | |||
|---|---|---|---|---|
| General and administrative expenses | 8,103,280 | |||
| Research and development expenses | 2,435,569 | |||
| Total operating costs | 10,538,849 | |||
| Interest income | 125,644 | |||
| Net loss | -10,413,205 | |||
| Basic EPS | -0.33 | |||
| Diluted EPS | -0.33 | |||
| Basic Average Shares | 31,653,094 | |||
| Diluted Average Shares | 31,653,094 | |||
Telomir Pharmaceuticals, Inc. (TELO)
Telomir Pharmaceuticals, Inc. (TELO)